Index of Veterinary Drugs
Functional Classes
Glossary

Clenbuterol

Functional Class: Adrenoceptor agonist

Search JECFA
Click the above link to access the relevant JECFA residue monograph(s)

Search WHO
Click the above link to access the relevant WHO evaluation

Maximum residue limits for Clenbuterol

Species

Tissue

MRL

Year of Adoption

Note

Cattle

Muscle

0.2 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Cattle

Tissue

Muscle

MRL

0.2 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Cattle

Liver

0.6 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Cattle

Tissue

Liver

MRL

0.6 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Cattle

Kidney

0.6 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Cattle

Tissue

Kidney

MRL

0.6 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Cattle

Fat

0.2 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Cattle

Tissue

Fat

MRL

0.2 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Cattle

Milk

0.05 µg/l

2003

-

Species

Cattle

Tissue

Milk

MRL

0.05 µg/l

Year of Adoption

2003

Note

-

Horse

Muscle

0.2 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Horse

Tissue

Muscle

MRL

0.2 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Horse

Liver

0.6 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Horse

Tissue

Liver

MRL

0.6 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Horse

Kidney

0.6 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Horse

Tissue

Kidney

MRL

0.6 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Horse

Fat

0.2 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Species

Horse

Tissue

Fat

MRL

0.2 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Showing 1 to 9 of 9 entries